"IPRC", was established in Jordan in 1997 having successfully passed four EMA and seven USFDA inspections; as well, has passed WHO inspection. IPRC successfully met the inspections conducted by South African MCC, the Turkish MoH and by the Regulatory bodies in MENA and GCC. IPRC has conducted more than 4500 bioequivalence & bioavailablity studies (1997-2022) in various therapeutic areas, successfuly submitted and accepted in the EU, USA, India, South Africa, Australia, New Zealand, Turkey, GCC and all around the MENA region. With 100 professionals, IPRC offers a broad range of services, including protocol development, protocol Regulatory submissions and approvals, clinical (180 beds), bioanalytical (22 LCMSMS and many HPLCs), monitoring and Regulatory services, PK and statistics, as well medical writing. IPRC has conducted more than 4,500 BE/BA & pharmacokinetics studies and has participated in many phases of Clinical Trials (I-IV) and is currently expanding that area. IPRC has been investing heavily in inhalers biostudies (PK, PD and usability studies) for many years. Our CRO has conducted many studies on behalf of EU & USA based sponsors on the following drugs, among others: Tiotropium, Salmeterol, Formoterol, Salbutamol, Budesonide, Indacaterol, Glycopyrronium, Fluticasone and combination of those. IPRC had distinguishly participated in Biosimilar development projects, e.g., Etanercept, Filgrastim, Denosumab and new monoclonal antibodies projects.
